Brooke may not know that, but she does know her partner is neglecting her home life.
Then there Fran and Cam – and where do we start with them? Perhaps not too surprisingly, Fran isn’t too impressed with this development.
So she and colleagues looked at data from the Partners Research Patient Data Registry on a total of 243 patients, 81 of whom were treated for dyslipidemia with statins for at least 3 months, and 162 who served as controls matched for age, gender, and liver disease severity.
In each group, 70.4% of patients were Child-Pugh A and 29.6% were Child-Pugh B/C; factors such as MELD, albumin, presence of varices and beta-blocker use weren't significantly different between groups.Clinicians have long been concerned that statins aren't safe in patients with severe liver disease, primarily because statins are metabolized in the liver and may put patients at greater risk of complications such as hepatic decompensation and liver failure.Recent studies, however, have suggested that statins aren't harmful in these patients, and that they may even diminish morbidity and mortality for liver patients with heart disease, Kumar said.In multivariate analyses, statin use was significantly associated with lower mortality (OR 0.49, 95% CI 0.29 to 0.81).Coronary artery disease and non-alcoholic steatohepatitis, on the other hand, were associated with increased mortality, they reported (OR 2.62, 95% CI 1.78 to 3.86 and OR 1.61, 95% CI 1.03 to 2.52, respectively).